1. 1. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clin Microbiol Rev. 2006;19(2):403-34. 2. Deitch EA. The Management of Burns. New England Journal of Medicine. 1990;323(18):1249-53. 3. Produced by: National Center for Injury Prevention and Control C, using WISQARS, Data Source: NEISS All Injury, population PobtCPSCfnoiBoCf, estimates. Accessed 10/13/2017. 4. Kravitz M. Immune consequences of burn injury. AACN clinical issues in critical care nursing. 1993;4(2):399-413. 5. Heideman M, Bengtsson A. The immunologic response to thermal injury. World Journal of Surgery. 1992;16(1):53-6. 6. Agnihotri N, Gupta V, Joshi RM. Aerobic bacterial isolates from burn wound infections and their antibiograms--a five-year study. Burns. 2004;30(3):241-3. 7. Cancio LC HP, McManus AT, et al. Burn wound infections. In: Holzheimer RG, Mannick JA, editors. Surgical Treatment: Evidence-Based and Problem-Oriented. Munich: Zuckschwerdt
2. 2001. Available from: https://www.ncbi.nlm.nih.gov/books/NBK6970/. 8. Pruitt BA, Jr., McManus AT, Kim SH, Goodwin CW. Burn wound infections: current status. World J Surg. 1998;22(2):135-45. 9. Safdar N, Marx J, Meyer NA, Maki DG. Effectiveness of preemptive barrier precautions in controlling nosocomial colonization and infection by methicillin-resistant Staphylococcus aureus in a burn unit. American journal of infection control. 2006;34(8):476-83. 10. http://www.who.int/antimicrobial-resistance/interagency-coordination-group/final-report/en/. WNTtWStffd-riW. 11. https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. Wplobfwnaaun. 12. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. The Lancet Infectious diseases. 2005;5(5):275-86. 13. Van Delden C, Iglewski BH. Cell-to-cell signaling and Pseudomonas aeruginosa infections. Emerg Infect Dis. 1998;4(4):551-60. 14. McVay CS, Velásquez M, Fralick JA. Phage Therapy of Pseudomonas aeruginosa Infection in a Mouse Burn Wound Model. Antimicrob Agents Chemother. 2007;51(6):1934-8. 15. Ventola CL. The Antibiotic Resistance Crisis: Part 1: Causes and Threats. Pharmacy and Therapeutics. 2015;40(4):277-83. 16. Dai T, Huang YY, Sharma SK, Hashmi JT, Kurup DB, Hamblin MR. Topical antimicrobials for burn wound infections. Recent Pat Antiinfect Drug Discov. 2010;5(2):124-51. 17. Johnson BA, Anker H, Meleney FL. BACITRACIN: A NEW ANTIBIOTIC PRODUCED BY A MEMBER OF THE B. SUBTILIS GROUP. Science (New York, NY). 1945;102(2650):376-7. 18. Palmieri TL, Greenhalgh DG. Topical treatment of pediatric patients with burns: a practical guide. American journal of clinical dermatology. 2002;3(8):529-34. 19. Sinha R, Agarwal RK, Agarwal M. Povidone iodine plus neosporin in superficial burns--a continuing study. Burns. 1997;23(7-8):626-8. 20. Munster AM. Treatment of invasive Enterobacter cloacae burn wound sepsis with topical nitrofurazone. The Journal of trauma. 1984;24(6):524-5. 21. Cho Lee AR, Leem H, Lee J, Park KC. Reversal of silver sulfadiazine-impaired wound healing by epidermal growth factor. Biomaterials. 2005;26(22):4670-6. 22. Klasen HJ. A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. Burns. 2000;26(2):131-8. 23. Fong J, Wood F. Nanocrystalline silver dressings in wound management: a review. Int J Nanomedicine. 2006;1(4):441-9. 24. Garner JP, Heppell PS. Cerium nitrate in the management of burns. Burns. 2005;31(5):539-47. 25. Zamora JL. Iodine toxicity. The Annals of thoracic surgery. 1986;41(4):462-3. 26. Ormiston MC, Seymour MT, Venn GE, Cohen RI, Fox JA. Controlled trial of Iodosorb in chronic venous ulcers. British medical journal (Clinical research ed). 1985;291(6491):308-10. 27. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagnosis and photodynamic therapy. 2004;1(4):279-93. 28. Rabea EI, Badawy ME, Stevens CV, Smagghe G, Steurbaut W. Chitosan as antimicrobial agent: applications and mode of action. Biomacromolecules. 2003;4(6):1457-65. 29. Mor A. Multifunctional host defense peptides: antiparasitic activities. The FEBS journal. 2009;276(22):6474-82. 30. McNulty C RG, Mortensen JE. . An overview of the topical antimicrobial agents used in the treatment of burn wounds. Continuing Education 2004;75. 31. Roope LSJ, Smith RD, Pouwels KB, Buchanan J, Abel L, Eibich P, et al. The challenge of antimicrobial resistance: What economics can contribute. Science (New York, NY). 2019;364(6435). 32. Chanishvili N. Phage therapy--history from Twort and d'Herelle through Soviet experience to current approaches. Advances in virus research. 2012;83:3-40. 33. Abedon ST, García P, Mullany P, Aminov R. Editorial: Phage Therapy: Past, Present and Future. Frontiers in Microbiology. 2017;8:981. 34. Dublanchet A, Bourne S. The epic of phage therapy. Can J Infect Dis Med Microbiol. 2007;18(1):15-8. 35. Kuipers S, Ruth MM, Mientjes M, de Sévaux RGL, van Ingen J. A Dutch Case Report of Successful Treatment of Chronic Relapsing Urinary Tract Infection with Bacteriophages in a Renal Transplant Patient. Antimicrob Agents Chemother. 2019;64(1). 36. Mu A, McDonald D, Jarmusch AK, Martino C, Brennan C, Bryant M, et al. Assessment of the microbiome during bacteriophage therapy in combination with systemic antibiotics to treat a case of staphylococcal device infection. Microbiome. 2021;9(1):92. 37. Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage Therapy. Antimicrob Agents Chemother. 2001;45(3):649-59. 38. Khalifa L, Gelman D, Shlezinger M, Dessal AL, Coppenhagen-Glazer S, Beyth N, et al. Defeating Antibiotic- and Phage-Resistant Enterococcus faecalis Using a Phage Cocktail in Vitro and in a Clot Model. Frontiers in Microbiology. 2018;9(326). 39. Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Current pharmaceutical biotechnology. 2010;11(1):28-47. 40. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage. 2011;1(2):66-85. 41. Skurnik M, Strauch E. Phage therapy: facts and fiction. International journal of medical microbiology : IJMM. 2006;296(1):5-14. 42. Abedon ST. Information Phage Therapy Research Should Report. Pharmaceuticals. 2017;10(2):43. 43. Górski A, Międzybrodzki R, Węgrzyn G, Jończyk-Matysiak E, Borysowski J, Weber-Dąbrowska B. Phage therapy: Current status and perspectives. Medicinal Research Reviews. 2020;40(1):459-63. 44. Aghaee BL, Khan Mirzaei M, Alikhani MY, Mojtahedi A, Maurice CF. Improving the Inhibitory Effect of Phages against Pseudomonas aeruginosa Isolated from a Burn Patient Using a Combination of Phages and Antibiotics. Viruses. 2021;13(2):334. 45. Wittebole X, De Roock S, Opal SM. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence. 2014 Jan 1;5(1):226-35. doi: 10.4161/viru.25991. Epub 2013 Aug 13. 46. Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa
3. a preliminary report of efficacy. Clin Otolaryngol. 2009 Aug;34(4):349-57. doi: 10.1111/j.1749-4486.2009.01973.x. 47. Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM, Taplitz R, Smith DM, Kerr K, Kumaraswamy M, Nizet V, Lin L, McCauley MD, Strathdee SA, Benson CA, Pope RK, Leroux BM, Picel AC, Mateczun AJ, Cilwa KE, Regeimbal JM, Estrella LA, Wolfe DM, Henry MS, Quinones J, Salka S, Bishop-Lilly KA, Young R, Hamilton T. Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrob Agents Chemother. 2017 Sep 22;61(10):e00954-17. doi: 10.1128/AAC.00954-17. Erratum in: Antimicrob Agents Chemother. 2018 Nov 26;62(12): PMID: 28807909
4. PMCID: PMC5610518. 48. Chan, B. K., Turner, P. E., Kim, S., Mojibian, H. R., Elefteriades, J. A., and Narayan, D. (2019). Publisher's Note: Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evolution, medicine, and public health, 2019(1), 35. 49. Jennes S, Merabishvili M, Soentjens P, Pang KW, Rose T, Keersebilck E, Soete O, François PM, Teodorescu S, Verween G, Verbeken G, De Vos D, Pirnay JP. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report. Crit Care. 2017 Jun 4;21(1):129. doi: 10.1186/s13054-017-1709-y. 50. Abedon ST. Phage Companies. companies.phage.org 51. Rose T, Verbeken G, Vos DD, Merabishvili M, Vaneechoutte M, Lavigne R, et al. Experimental phage therapy of burn wound infection: difficult first steps. Int J Burns Trauma. 2014;4(2):66-73. 52. Jault P, Leclerc T, Jennes S, Pirnay JP, Que YA, Resch G, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. The Lancet Infectious diseases. 2019;19(1):35-45. 53. Kumari S, Harjai K, Chhibber S. Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by Klebsiella pneumoniae B5055. Journal of medical microbiology. 2011;60(2):205-10. 54. Kumari S, Harjai K, Chhibber S. Bacteriophage treatment of burn wound infection caused by Pseudomonas aeruginosa PAO in BALB/c mice. Am J Biomed Sci. 2009;1(4):385-94. 55. Dallal MMS, Nikkhahi F, Alimohammadi M, Douraghi M, Rajabi Z, Foroushani AR, Azimi A, Fardsanei F. Phage Therapy as an Approach to Control Salmonella enterica serotype Enteritidis Infection in Mice. Rev Soc Bras Med Trop. 2019 Nov 14;52:e20190290. doi: 10.1590/0037-8682-0290-2019. PMID: 31778422. 56. Vaitekenas A, Tai AS, Ramsay JP, Stick SM, Kicic A. Pseudomonas aeruginosa Resistance to Bacteriophages and Its Prevention by Strategic Therapeutic Cocktail Formulation. Antibiotics. 2021;10(2):145. 57. Knezevic P, Curcin S, Aleksic V, Petrusic M, Vlaski L. Phage-antibiotic synergism: a possible approach to combatting Pseudomonas aeruginosa. Research in Microbiology. 2013;164(1):55-60. 58. Khalid A, Lin RCY, Iredell JR. A Phage Therapy Guide for Clinicians and Basic Scientists: Background and Highlighting Applications for Developing Countries. Frontiers in Microbiology. 2021;11(3417). 59. Alves DR, Gaudion A, Bean JE, Perez Esteban P, Arnot TC, Harper DR, et al. Combined use of bacteriophage K and a novel bacteriophage to reduce Staphylococcus aureus biofilm formation. Appl Environ Microbiol. 2014;80(21):6694-703. 60. Phee A, Bondy-Denomy J, Kishen A, Basrani B, Azarpazhooh A, Maxwell K. Efficacy of bacteriophage treatment on Pseudomonas aeruginosa biofilms. Journal of endodontics. 2013;39(3):364-9. 61. Chegini Z, Khoshbayan A, Taati Moghadam M, Farahani I, Jazireian P, Shariati A. Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review. Annals of Clinical Microbiology and Antimicrobials. 2020;19(1):45. 62. Tkhilaishvili T, Wang L, Perka C, Trampuz A, Gonzalez Moreno M. Using Bacteriophages as a Trojan Horse to the Killing of Dual-Species Biofilm Formed by Pseudomonas aeruginosa and Methicillin Resistant Staphylococcus aureus. Frontiers in microbiology. 2020;11:695-. 63. Tian F, Li J, Nazir A, Tong Y. Bacteriophage-A Promising Alternative Measure for Bacterial Biofilm Control. Infection and Drug Resistance. 2021;14:205.
5. Burn Wound Infections